AIM: To determine whether SP-TAT-apoptin induces apoptosis and also maintains its tumor cell specificity. METHODS: In this study, we designed a secretory protein by adding a secretory signal peptide (SP) to the N terminus of Transactivating Transcription (TAT)-apoptin (SP-TAT-apoptin), to test the hypothesis that it gains an additive bystander effect as an anti-cancer therapy. We used an artificial human secretory SP whose amino acid sequence and corresponding cDNA sequence were generated by the SP hidden Markov model. RESULTS: In human liver carcinoma HepG2 cells, SP-TAT-apoptin expression showed a diffuse pattern in the early phase after transfection. After 48 h, however, it translocated into the nuclear compartment and caused massive apoptotic cell death, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and annexin-V binding assay. SP-TAT-apoptin did not, however, cause any cell death in non-malignant human umbilical vein endothelial cells (HUVECs). Most importantly, the conditioned medium from Chinese hamster ovary (CHO) cells transfected with SP-TAT-apoptin also induced significant cell death in HepG2 cells, but not in HUVECs. CONCLUSION: The data demonstrated that SP-TAT-apoptin induces apoptosis only in malignant cells, and its secretory property might greatly increase its potency once it is delivered in vivo for cancer therapy.
AIM: To determine whether SP-TAT-apoptin induces apoptosis and also maintains its tumor cell specificity. METHODS: In this study, we designed a secretory protein by adding a secretory signal peptide (SP) to the N terminus of Transactivating Transcription (TAT)-apoptin (SP-TAT-apoptin), to test the hypothesis that it gains an additive bystander effect as an anti-cancer therapy. We used an artificial human secretory SP whose amino acid sequence and corresponding cDNA sequence were generated by the SP hidden Markov model. RESULTS: In humanliver carcinoma HepG2 cells, SP-TAT-apoptin expression showed a diffuse pattern in the early phase after transfection. After 48 h, however, it translocated into the nuclear compartment and caused massive apoptotic cell death, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and annexin-V binding assay. SP-TAT-apoptin did not, however, cause any cell death in non-malignant human umbilical vein endothelial cells (HUVECs). Most importantly, the conditioned medium from Chinese hamster ovary (CHO) cells transfected with SP-TAT-apoptin also induced significant cell death in HepG2 cells, but not in HUVECs. CONCLUSION: The data demonstrated that SP-TAT-apoptin induces apoptosis only in malignant cells, and its secretory property might greatly increase its potency once it is delivered in vivo for cancer therapy.
Authors: Xiang Liu; S Elojeimy; A M El-Zawahry; D H Holman; A Bielawska; J Bielawski; S Rubinchik; G-W Guo; J-Y Dong; T Keane; Y A Hannun; M Tavassoli; James S Norris Journal: Mol Ther Date: 2006-08-01 Impact factor: 11.454
Authors: Ha Yong Song; Ji Ae Lee; Sung Mi Ju; Ki-Yeon Yoo; Moo Ho Won; Hyung-Joo Kwon; Won Sik Eum; Sang Ho Jang; Soo Young Choi; Jinseu Park Journal: Biochem Pharmacol Date: 2007-12-03 Impact factor: 5.858
Authors: Eri Kubo; Nigar Fatma; Yoshio Akagi; David R Beier; Sanjay P Singh; Dhirendra P Singh Journal: Am J Physiol Cell Physiol Date: 2008-01-09 Impact factor: 4.249
Authors: Georg Gdynia; Judith Lehmann-Koch; Sebastian Sieber; Katrin E Tagscherer; Anne Fassl; Hanswalter Zentgraf; Shu-Ichi Matsuzawa; John C Reed; Wilfried Roth Journal: Apoptosis Date: 2008-03 Impact factor: 4.677
Authors: S Maddika; E Wiechec; S R Ande; I K Poon; U Fischer; S Wesselborg; D A Jans; K Schulze-Osthoff; M Los Journal: Oncogene Date: 2007-12-03 Impact factor: 9.867
Authors: Claude Backendorf; Astrid E Visser; A G de Boer; Rhyenne Zimmerman; Mijke Visser; Patrick Voskamp; Ying-Hui Zhang; Mathieu Noteborn Journal: Annu Rev Pharmacol Toxicol Date: 2008 Impact factor: 13.820